BioCryst bags $250M in a debt and roy­al­ty deal as the ex­ec­u­tive team preps a new drug launch for HAE

Three days af­ter land­ing an FDA OK for their HAE drug bero­tral­stat, BioCryst $BCRX now has some cash to see how far they can go in com­mer­cial­iz­ing the ther­a­py as Or­ladeyo.

The biotech re­port­ed Mon­day morn­ing that they’ve inked a deal with Roy­al­ty Phar­ma that trades a chunk of their rev­enue from the drug for cash in hand. Roy­al­ty is pay­ing out $125 mil­lion up­front, with a $200 mil­lion cred­it fa­cil­i­ty from Athyri­um Cap­i­tal Man­age­ment that is be­ing tapped for $125 mil­lion right off the bat. The rest will be held in re­serve.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER